Eighty percent of lung cancer cases are diagnosed too late, not because the signals aren't there, but because nobody was looking at the right moment. Prashant Warier, co-founder and CEO of Qure.ai, joins Craig Smith to explain how his company is changing that using a tool most people already encounter: the routine chest X-ray. Cure's Lung Nodule Malignancy Risk Score - validated in the CREATE study - analyzes X-rays people get for unrelated reasons, identifies high-risk nodules, and flags which patients need follow-up CT scans. The result is a detection rate of 54 positive patients out of 100 flagged as high-risk, compared to the 2 out of 100 found by standard CT screening programs. That's not a marginal improvement. That's a different category of outcome.
The conversation covers the full landscape of where AI diagnostics actually stands today: the 15 million TB screening X-rays that Cure reads autonomously every year across 70 countries with no radiologist in the loop, because in many of those countries there are only two radiologists for the entire nation; the 26 FDA clearances and 200-plus published studies that underpin the company's clinical credibility; and the regulatory barriers that currently prevent patients from uploading their own scans and getting an AI read directly. Warier also makes his sharpest prediction: within 5 to 10 years, primary care will be AI-first, the first conversation you have when something feels wrong won't be with a doctor, it will be with an AI. Based on what Cure is already doing at scale today, that timeline is harder to dismiss than it might sound.
Subscribe to Eye on A.I. for weekly conversations with the people building and deploying the future of AI.